

REED SMITH LLP  
599 Lexington Avenue  
New York, New York 10022  
Telephone: (212) 521-5400  
Ann V. Kramer

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

**In re:**

**PURDUE PHARMA L.P., et al.,  
Debtors.<sup>1</sup>**

**Chapter 11**

**Case No. 19-23649 (RDD)**

**(Jointly Administered)**

**NOTICE OF FILING OF PROPOSED ORDER GRANTING THE FINAL  
APPLICATION OF REED SMITH LLP AS AN ORDINARY COURSE PROFESSIONAL  
FOR COMPENSATION FOR SERVICES RENDERED IN EXCESS OF THE TIER 1  
OCP CAP FOR THE PERIOD FROM  
SEPTEMBER 1, 2021 THROUGH FEBRUARY 28, 2022**

**PLEASE TAKE NOTICE** that on April 18, 2022, Reed Smith LLP (“**Reed Smith**”) filed the *Final Application of Reed Smith LLP as an Ordinary Course Professional for Compensation for Services Rendered in Excess of the Tier 1 OCP Cap for the Period From September 1, 2021 Through February 28, 2022* [ECF No. 4671] pursuant to the *Order Authorizing Debtors to Employ Professionals Used in the Ordinary Course of Business Nunc Pro Tunc to the Petition Date* [ECF No. 548].

---

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors’ corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

**PLEASE TAKE FURTHER NOTICE** that on April 28, 2022, the above-captioned debtors and debtors-in-possession (collectively, the “**Debtors**”) filed the *Notice of Hearing on Final Application of Reed Smith LLP as an Ordinary Course Professional for Compensation For Services Rendered in Excess of the Tier 1 OCP Cap for the Period From September 1, 2021 Through February 28, 2022* [ECF No. 4710].

**PLEASE TAKE FURTHER NOTICE** that the Debtors hereby file a Proposed Order Granting the Final Application of Reed Smith LLP as an Ordinary Course Professional for Compensation for Services Rendered in Excess of the Tier 1 OCP Cap for the Period from September 1, 2021 through February 28, 2022 (the “**Proposed Order**”). The Proposed Order is attached hereto as **Exhibit A**.

**PLEASE TAKE FURTHER NOTICE** that a copy of the Proposed Order and all related papers may be obtained free of charge by visiting the website of Kroll Restructuring Administration at <https://restructuring.ra.kroll.com/purduepharma>. You may also obtain copies of any pleadings by visiting the Bankruptcy Court’s website at <http://www.nysb.uscourts.gov> in accordance with the procedures and fees set forth therein.

*[Remainder of page intentionally left blank]*

Dated: May 12, 2022  
New York, New York

Respectfully submitted,

/s/ DRAFT

Ann V. Kramer  
Reed Smith LLP

**EXHIBIT A**

**Proposed Order**

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

**In re:**

**PURDUE PHARMA L.P., *et al.*,**

**Debtors.<sup>1</sup>**

**Chapter 11**

**Case No. 19-23649 (RDD)**

**(Jointly Administered)**

**[PROPOSED] ORDER GRANTING THE FINAL APPLICATION OF REED SMITH  
LLP AS AN ORDINARY COURSE PROFESSIONAL FOR COMPENSATION FOR  
SERVICES RENDERED IN EXCESS OF THE TIER 1 OCP CAP FOR THE PERIOD  
FROM SEPTEMBER 1, 2021 THROUGH FEBRUARY 28, 2022**

Upon consideration of the application, dated April 18, 2022 (the “Application”) filed by Reed Smith LLP (“Reed Smith”) pursuant to sections 327, 330 and 331 of title 11 of the United States Code (the “Bankruptcy Code”), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), Rule 2016-1 of the Local Rules of Bankruptcy Procedure, incorporating the *Amended Guidelines for Fees and Disbursements for Professionals in the Southern District of New York Bankruptcy Cases* promulgated by the Board of Judges for the United States Bankruptcy Court for the Southern District of New York [General Order M-447], the *United States Trustee’s Guidelines for Reviewing Applications for Compensation and Reimbursement of Expenses Filed Under 11 U.S.C. § 330 for Attorneys in Larger Chapter 11 Cases* effective as of November 1, 2013, and the *Order Authorizing Debtors to Employ Professionals Used in the Ordinary Course of Business Nunc Pro Tunc to the Petition Date* [ECF No. 548] (the “OCP Order”), seeking

---

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors’ corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

allowance of compensation for actual and necessary professional services in excess of the Tier 1 OCP Cap<sup>2</sup> in the amount of \$285,393.00 from September 1, 2021 through February 28, 2022 (the “Fee Period”); and an independent fee examiner (the “Fee Examiner”) having been appointed in these cases in accordance with the *Order Authorizing Appointment of Independent Fee Examiner Pursuant to 11 U.S.C. § 105(a) and Modifying Interim Compensation Procedures for Certain Professionals Employed Pursuant to 11 U.S.C. § 327* [ECF No. 1023] (the “Fee Examiner Order”); and the Fee Examiner having reviewed the Application in accordance with the Fee Examiner Order; and the Fee Examiner and Reed Smith having agreed to the recommended fee reductions as set forth on Schedule A hereto; and the Fee Examiner having no objection to payment of Reed Smith’s fees in the amount set forth on Schedule A hereto under the column heading “Amount of Fees in Excess of Tier 1 OCP Cap Allowed”; and due and sufficient notice having been provided pursuant to Bankruptcy Rules 2002(a)(6) and (c)(2) and the OCP Order, and it appearing that no other or further notice need be provided; and a hearing having been held on May 18, 2022 to consider the Application (the “Hearing”); and the Court having jurisdiction over this matter pursuant to 28 U.S.C. §§ 157(a)-(b) and 1334(b) and the Amended Standing Order of Reference M-431, dated January 31, 2012 (Preska, C.J.); and this matter being a core proceeding under 28 U.S.C. § 157(b)(2); and venue being proper before the Court pursuant to 28 U.S.C. §§ 1408 and 1409; and upon the record of all of the proceedings had before the Court; and there being no objections to the relief granted herein; and it appearing that the amount set forth on Schedule A for which compensation is allowed hereby was actual, reasonable, and necessary; and good and sufficient cause appearing therefor,

---

<sup>2</sup> Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the OCP Order or the Application, as appropriate.

IT IS HEREBY ORDERED THAT:

1. The Application is granted as set forth herein.
2. Reed Smith is awarded compensation for professional services rendered during the Fee Period in excess of the Tier 1 OCP Cap in the amount set forth on Schedule A hereto under the column heading “Amount of Fees in Excess of Tier 1 OCP Cap Allowed.”
3. The Debtors are authorized and directed to pay Reed Smith promptly the amounts of fees approved by this Order, to the extent such amounts have not previously been paid.
4. This Court shall retain jurisdiction to hear and determine all matters arising from or related to this Order.

Dated: May [●], 2022  
White Plains, New York

---

HONORABLE ROBERT D. DRAIN  
UNITED STATES BANKRUPTCY JUDGE

**Schedule A****Application for Fees in Excess of the Tier 1 OCP Cap****Case No:** 19-23649 (RDD)**Case Name:** In re Purdue Pharma L.P., *et al.*

<b>Applicant</b>	<b>Date and Docket Number of Application</b>	<b>Time Period Covered by Application</b>	<b>Amount of Fees in Excess of Tier 1 OCP Cap Requested</b>	<b>Agreed Recommended Reduction of Fees</b>	<b>Amount of Fees in Excess of Tier 1 OCP Cap Allowed</b>
Reed Smith LLP	April 18, 2022 ECF No. 4671	9/01/2021 – 2/28/2022	\$285,393.00	\$3,839.50	\$281,553.50

Date Order Signed: 5/[●]/2022

Initials: [\_\_\_\_\_]